Arcellx price target cut to $82 by Redburn, Stifel sets $127 target on safety data
On February 12, Rothschild & Co Redburn downgraded Arcellx from Buy to Neutral, cutting its price target from $113 to $82. On February 9, Stifel reaffirmed a Buy rating with a $127 target after lab data showed anito-cel’s lower unintended immune activity and fewer off-target effects than rival CAR-T therapies.
1. Redburn Downgrade and Revised Price Target
On February 12, Rothschild & Co Redburn downgraded Arcellx from Buy to Neutral and lowered its price target from $113 to $82, citing rising competition in CAR-T therapies and a cautious outlook on the company's CAR-T cell therapy class.
2. Stifel Reaffirmation and Lab Data Highlights
On February 9, Stifel reaffirmed a Buy rating with a $127 price target, highlighting laboratory results presented at the TANDEM meeting that showed anito-cel exhibited lower unintended immune activity and fewer off-target effects compared with rival CAR-T treatments.
3. Company Pipeline and Strategic Positioning
Arcellx leverages its proprietary D-Domain technology to develop CAR-T therapies targeting BCMA in relapsed/refractory multiple myeloma (ACLX-001) and CD123 in AML/MDS (ACLX-002), positioning anito-cel as a potential best-in-class candidate in a competitive immunotherapy landscape.